Stem cell-derived retinal cells need primary cilia to support survival of light-sensing photoreceptors
Scientists at the National Eye Institute (NEI), part of the National Institutes of Health, report that tiny tube-like protrusions called primary cilia on cells of the retinal pigment epithelium (RPE)—a layer of cells in the back of the eye—are essential for the survival of the retina’s light-sensing photoreceptors. The discovery has advanced efforts to make stem cell-derived RPE for transplantation into patients with geographic atrophy, otherwise known as dry age-related macular degeneration (AMD), a leading cause of blindness in the U.S. The study appears in the January 2 Cell Reports.
“We now have a better idea about how to generate and replace RPE cells, which appear to be among the first type of cells to stop working properly in AMD,” said the study’s lead investigator, Kapil Bharti, Ph.D., Stadtman investigator at the NEI. Bharti is leading the development of patient stem cell-derived RPE for an AMD clinical trial set to launch in 2018.
In a healthy eye, RPE cells nourish and support photoreceptors, the cells that convert light into electrical signals that travel to the brain via the optic nerve. RPE cells form a layer just behind the photoreceptors. In geographic atrophy, RPE cells die, which causes photoreceptors to degenerate, leading to vision loss.
Bharti and his colleagues are hoping to halt and reverse the progression of geographic atrophy by replacing diseased RPE with lab-made RPE. The approach involves using a patient’s blood cells to generate induced-pluripotent stem cells (iPSCs), cells capable of becoming any type of cell in the body. iPSCs are grown in the laboratory and then coaxed into becoming RPE for surgical implantation.
Attempts to create functional RPE implants, however, have hit a recurring obstacle: iPSCs programmed to become RPE cells have a tendency to get developmentally stuck, said Bharti. “The cells frequently fail to mature into functional RPE capable of supporting photoreceptors. In cases where they do mature, however, RPE maturation coincides with the emergence of primary cilia on the iPSC-RPE cells.”
The researchers tested three drugs known to modulate the growth of primary cilia on iPSC-derived RPE. As predicted, the two drugs known to enhance cilia growth significantly improved the structural and functional maturation of the iPSC-derived RPE. One important characteristic of maturity observed was that the RPE cells all oriented properly, correctly forming a single, functional monolayer. The iPSC-derived RPE cell gene expression profile also resembled that of adult RPE cells. And importantly, the cells performed a crucial function of mature RPE cells: they engulfed the tips of photoreceptor outer segments, a pruning process that keeps photoreceptors working properly.
By contrast, iPSC-derived RPE cells exposed to the third drug, an inhibitor of cilia growth, demonstrated severely disrupted structure and functionality.
As further confirmation of their observations, when the researchers genetically knocked down expression of cilia protein IFT88, the iPSC-derived RPE showed severe maturation and functional defects, as confirmed by gene expression analysis. Tissue staining showed that knocking down IFT88 led to reduced iPSC-derived RPE cell density and functional polarity, i.e., cells within the RPE tissue pointed in the wrong direction.
Bharti and his group found similar results in iPSC-derived lung cells, another type of epithelial cell with primary cilia. When iPSC-derived lung cells were exposed to drugs that enhance cilia growth, immunostaining confirmed that the cells looked structurally mature.
The report suggests that primary cilia regulate the suppression of the canonical WNT pathway, a cell signaling pathway involved in embryonic development. Suppression of the WNT pathway during RPE development instructs the cells to stop dividing and to begin differentiating into adult RPE, according to the researchers.
The researchers also generated iPSC-derived RPE from a patient with ciliopathy, a disorder that causes severe vision loss due to photoreceptor degeneration. The patient’s ciliopathy was associated with mutations of cilia gene CEP290. Compared to a healthy donor, iPSC-derived RPE from the ciliopathy patient had cilia that were smaller. The patient’s iPSC-derived RPE also had maturation and functional defects similar to those with IFT88 knockdown.
Further studies in a mouse model of ciliopathy confirmed an important temporal relationship: Looking across several early development stages, the RPE defects preceded the photoreceptor degeneration, which provides additional insights into ciliopathy-induced retinal degeneration.
The Latest on: Dry age-related macular degeneration
- US FDA accepts Novartis' BLA for brolucizumab to treat wet age-related macular degeneration on April 16, 2019 at 8:30 pm
and dry eye (2.7% and 3.0%). neovascular age-related macular degeneration (nAMD or wet AMD) is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America ... […]
- LumiThera begins LIGHTSITE II study to treat dry age-related macular degeneration on April 15, 2019 at 2:30 am
LumiThera Inc, a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, has begun enrolling patients in a European Union multi-center ... […]
- LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration on April 11, 2019 at 4:49 am
"I am delighted that we are able to offer some of our patients this very exciting new treatment," remarked Professor Ben Burton, Visiting Professor at the University of East Anglia, and ... […]
- Macular Degeneration Treatment Market: Application of anti-VEGFs to treat Wet AMD Soars on April 10, 2019 at 12:09 am
Age-related macular degeneration is one of the main causes of irreversible ... manufacturers are launching novel products for the treatment of late stage of dry AMD and wet AMD. This report offers a ... […]
- Vitamins, new treatments offer hope for people with macular degeneration on April 5, 2019 at 4:30 am
It is frequently referred to as age-related macular degeneration ... Chaturvedi explains that there are two main types of macular degeneration: dry and wet. “In the dry type of AMD, the deterioration ... […]
- The Basics About Age-Related Macular Degeneration on March 26, 2019 at 5:07 am
Age-related macular degeneration (AMD ... adding that she’s still able to read. Unfortunately, for dry macular degeneration, there are no such treatments. Many studies have proven unfruitful for the ... […]
- Macular Degeneration Treatment Market Is Estimated to Value $11.4 Billion by 2026: CAGR 6.6% on March 18, 2019 at 11:52 am
Macular Degeneration Treatment Market (By Disease Indication: Dry Age-related Macular Degeneration Treatment, Wet Age-related Macular Degeneration Treatment, Others; By Drug Class: Anti-vascular ... […]
- Macular degeneration treatment market size worth around US $11.4 billion by 2026: Acumen Research and Consulting on March 16, 2019 at 7:05 am
On the basis of disease indication, the global macular degeneration treatment market is segmented into dry age-related macular degeneration treatment, wet age-related macular degeneration treatment, ... […]
- What is wet macular degeneration on February 18, 2019 at 3:56 pm
It could be age-related macular degeneration ... Bakri says there are two kinds of macular degeneration: wet and dry. “The dry kind usually comes on first, and when we look in the retina of the dry ... […]
- What you need to know about wet macular degeneration on February 14, 2019 at 6:35 am
... macular degeneration and dry macular degeneration. You're getting older and notice you're not seeing as well. You try out readers, but everything just seems blurry. And straight lines seem wavy. ... […]
via Google News and Bing News